期刊文献+

丙基硫氧嘧啶、普萘洛尔联合用药治疗亚临床甲亢合并阵发性房颤的疗效分析 被引量:6

下载PDF
导出
摘要 目的探讨丙基硫氧嘧啶联合普萘洛尔联合用药治疗亚临床甲亢合并阵发性房颤的临床疗效。方法选取2012年6月至2013年12月64例亚临床甲亢合并阵发性房颤患者,随机分成两组,治疗组32例采用丙基硫氧嘧啶联合普萘洛尔用药治疗,给予丙基硫氧嘧啶50 mg/d,口服,同时给予普萘洛尔10 mg/d,口服;对照组32例给予等量的安慰剂治疗。观察两组患者治疗前后FT3、FT4、TSH、心功能、TGAb阳性率、TPOAb阳性率变化情况。结果治疗组治疗后FT4较治疗前明显下降(P<0.01),TSH较治疗前显著升高(P<0.01)。两组治疗后,TGAb、TPOAb阳性率前后均无显著差异。治疗组治疗后平均心率显著下降(P<0.05)。结论丙基硫氧嘧啶联合普萘洛尔对于亚临床甲亢合并阵发性房颤,可协同改善血清TSH水平,降低甲状腺功能减退现象,改善心脏功能,有效缓解房颤的发生。
作者 孙权
出处 《中国医药指南》 2015年第5期181-182,共2页 Guide of China Medicine
  • 相关文献

参考文献7

二级参考文献36

  • 1潘素琼,朱秀清.甲状腺机能亢进症合并重症肌无力研究进展[J].华南国防医学杂志,2004,18(6):27-29. 被引量:9
  • 2陈缬珠.实用内科学·第10版[M].北京:人民卫生出版社,1998:1027.
  • 3中华人民共和国卫生部颁布制定.中药新药治疗甲状腺功能亢进的临床研究指导原则[S].2002:5.
  • 4FrancisS.greenspan,gordonJ.Strewler.基础与临床内分泌学·第5版[M].西安:世界图书出版西安公司,2001,5(1):245-246.
  • 5李学增.外科护理学[M].北京:人民卫生出版社,1991.72-80.
  • 6Surks M I, Ortiz E, Daniels G H, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and man- agement[J]. JAMA, 2004, 291: 228.
  • 7Auer J, Seheibner P, Mische T, et al. Subclinical hyperthy- roidism as a risk factor for atrial fibrillation[J]. Am Hearl J, 2001, 142: 838.
  • 8Rosario P W. Bone and Heart Abnormalities of Subclinical Hyperthyroidism in Women Below the Age of 65 Years [ J ]. Arq Bras Endocrinol Metabol, 2008, 52(9) : 1448.
  • 9中华医学会内分泌分会,中华医学会围产医学分会.妊娠和产后甲状腺疾病诊治指南[J].中华内分泌代谢杂志,2012,28(2):354:69.
  • 10Mestman JH. Hyperthyroidism in pregnancy [ J ]. Curr Opin Endo- crinol Diabetes Obes, 2012,19 ( 5 ) : 394 -401.

共引文献55

同被引文献57

  • 1陈威,崇巍,单忠艳,李玉姝,关海霞,范晨玲,滕卫平.甲状腺刺激性抗体、碘摄入量与亚临床甲亢发病及预后的关系[J].中国免疫学杂志,2005,21(9):674-677. 被引量:5
  • 2Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease., scientific review and guidelines for diagnosis and management [J]. JAMA, 2004, 291(2).. 228-238.
  • 3Biondi B, Palmieri EA, Klain M, et al. Subclinical hyperthyroidism: clinical features and treatment options [J].Eur J Endocrinol, 2005, 152(1): 1-9.
  • 4Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction[J].. Endocr Rev, 2008, 29(1) : 76-131.
  • 5Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists [J ]. Thyroid, 2011, 21(6): 593-642.
  • 6Cooper DS, Biondi B. Subclinical thyroid disease[J]. Lancet, 2012, 379(9821): 1142-1154.
  • 7Mitchell AL, Pearce SH. How should we treat patients with low serum thyrotropin concentrations? [J]. Clin Endocrinol (Oxf), 2010, 72(3): 292-296.
  • 8Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum [J]. Thyroid, 2011, 21(10).. 1081-1125.
  • 9De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum an Endocrine Society clinical practice guideline [J]. J Clin Endocrinol Metab, 2012, 97(8) 2543-2565.
  • 10Nathan N, Sullivan SD. Thyroid disorders during pregnancy[J]. Endocrinol Metab Clin North Am, 2014, 43(2): 573- 579.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部